AstraZeneca’s rare disease unit Alexion has penned a $825 million deal for adeno-associated virus (AAV) capsids from existing ...

AI is fundamental to the competitive strategies of the most advanced healthcare and pharmaceutical firms. Here is how they ...

AstraZeneca may have washed its hands of AZD4041 after the opioid use disorder (OUD) prospect demonstrated a potential drug-drug interaction last year, but the pharma’s development partner, Eolas T | ...

WPP shares rallied following yesterday’s slump, putting on 7.8p to 436.4p after announcing Microsoft executive Cindy Rose as ...

Looking back over the past five years, it's clear that healthcare professionals (HCPs) have faced incredible pressure and ...

IonQ talks algorithmic qubits, AQ, rather than inflated raw qubit counts. Their Forte and Forte Enterprise quantum systems ...

Merck has pulled off another acquisition which fits in its “sweet spot,” as described by CEO Rob Davis, paying $10 billion ...

Understanding these trends will equip life sciences leaders with the knowledge to convert volatility into sustainable ...

AstraZeneca’s new CEO shakes up leadership team Hannah Blake pharmaphorum AstraZeneca has revealed it has expanded membership of its Senior Executive Team, which comes into effect immediately.

Why is AstraZeneca considering the switch? CEO Pascal Soriot is said to be frustrated with the UK’s regulatory regime and the ...

One of Wood's favorite AI stocks has been criticized by CNBC host Jim Cramer multiple times in 2025, including this week.

JCR announced that it has entered into a license agreement with Alexion, for JCR’s new, proprietary JUST-AAV capsids to ...